Literature DB >> 20146632

Toll-like receptors as therapeutic targets in gastrointestinal diseases.

Pedro Pimentel-Nunes1, João Bruno Soares, Roberto Roncon-Albuquerque, Mário Dinis-Ribeiro, Adelino F Leite-Moreira.   

Abstract

IMPORTANCE OF THE FIELD: Toll-like receptors (TLRs) are innate immunity receptors that recognize several different antigens, initiating immunological/inflammatory responses. Recent evidence associates numerous pathophysiological processes and diseases with dysregulated activation of these receptors, conferring a potential therapeutic value to their modulation. AREAS COVERED IN THIS REVIEW: The aim of this systematic review that covers literature from the past 10 years is to address the role of TLRs in the pathophysiology of gastrointestinal (GI) diseases as well as the therapeutic potential of modulating TLRs' signaling pathways in GI pathology. WHAT THE READER WILL GAIN: This review shows that TLRs play an important role in the pathophysiology of several GI diseases and that modulating TLRs signaling pathways may have an enormous therapeutic potential. Different methods for modulation of TLRs' activity in GI tract, with direct agonists/antagonists but also with non-specific substances, like antibiotics or probiotics, are presented. TAKE HOME MESSAGE: Even though TLRs modulators have been used for therapy in some GI diseases, further research, particularly in humans, is needed in order to establish the precise role of the different TLRs in the diverse GI diseases and to motivate clinical trials that consider TLRs as therapeutic targets in GI pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146632     DOI: 10.1517/14728221003642027

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  20 in total

1.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

2.  Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis.

Authors:  Tian Rong Wang; Jiang Chen Peng; Yu Qi Qiao; Ming Ming Zhu; Di Zhao; Jun Shen; Zhi Hua Ran
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 3.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

4.  Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia.

Authors:  Pedro Pimentel-Nunes; Luís Afonso; Paula Lopes; Roberto Roncon-Albuquerque; Nádia Gonçalves; Rui Henrique; Luís Moreira-Dias; Adelino F Leite-Moreira; Mário Dinis-Ribeiro
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

5.  Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases.

Authors:  Alejandra de Moreno de Leblanc; Silvina Del Carmen; Meritxell Zurita-Turk; Clarissa Santos Rocha; Maarten van de Guchte; Vasco Azevedo; Anderson Miyoshi; Jean Guy Leblanc
Journal:  ISRN Gastroenterol       Date:  2011-02-08

6.  Long-lasting effect of infant rats endotoxemia on heat shock protein 60 in the pancreatic acinar cells: involvement of toll-like receptor 4.

Authors:  Joanna Bonior; Jolanta Jaworek; Michalina Kot; Stanisław J Konturek; Piotr Pierzchalski
Journal:  Int J Inflam       Date:  2012-05-22

7.  Effect of Helicobacter pylori eradication on TLR2 and TLR4 expression in patients with gastric lesions.

Authors:  Aline Cristina Targa Cadamuro; Ana Flávia Teixeira Rossi; Joice Matos Biselli-Périco; Patrícia Fucuta Pereira; Edla Polsinelli Bedin Mascarin Do Vale; Ricardo Acayaba; Kátia Ramos Moreira Leite; Eny Maria Goloni-Bertollo; Ana Elizabete Silva
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

Review 8.  Toll-like receptors in pathophysiology of liver diseases.

Authors:  Safak Kiziltas
Journal:  World J Hepatol       Date:  2016-11-18

Review 9.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

10.  The relationship between expression of Toll-like receptor 4 in chronic hepatitis C patients and different stages of liver fibrosis.

Authors:  Salem Youssef Mohamed; Ehab Fawzy Mostafa; Amr Shaaban Hanafy; Hesham Atia; Ashraf Metwally; Ayman M Marei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.